Skip to content

Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy

Comparison of Administration of Indocyanine Green (ICG) for Image-Guided Laparoscopic Cholocystectomy- A Randomized, Controlled, Prospective Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04908826
Enrollment
240
Registered
2021-06-01
Start date
2022-01-03
Completion date
2023-01-01
Last updated
2022-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Injury, Cholangiography, Choledocholithiasis, Cholelithiasis; Bile Duct, Indocyanine Green, Intraoperative Complications, Laparoscopic; Cholecystectomy, Post-Op Complication, Stone - Biliary

Brief summary

The aim of the trial is to compare the routes of administration of indocyanine green (ICG) during laparoscopic cholocystectomy.

Detailed description

Laparoscopic cholecystectomy is now the method of choice for the treatment of symptomatic and complicated gallstones. There are two major problems that can occur during and after a laparoscopic cholecystectomy. These are the remaining stones in the bile duct and the iatrogenic injuries of the bile ducts. Iatrogenic bile duct injuries are the most difficult complication of cholecystectomy and are a clinical entity that needs multifactorial treatment as it significantly increases morbidity, mortality and overall cost. Intraoperative cholangiography is used to prevent these complications. Intraoperative cholangiography is the traditional method of identifying bile duct anatomy during laparoscopic cholecystectomy. This method has the disadvantages that both the patient and the staff are exposed to radiation, while in order to perform it, catheterization of the cystic duct must be performed, which requires surgical procedures that increase the time of the operation, while in some cases it is not technically easy. Finally, with the intraoperative cholangiography, the injuries of the bile ducts are detected, after they have taken place, therefore it helps in their timely diagnosis but does not limit the frequency of their occurrence. Indocyanine green is a sterile, anionic, water-soluble but relatively hydrophobic tricarbocyanine molecule with a molecular weight of 751.4. It was developed in 1955 at Kodak Laboratories and in 1959 was approved for clinical use by the FDA. It has the property of fluorescing, after its administration, with a maximum absorption at 800 nm after exposure to infrared lighting. Its use offers an image of high clarity and sensitivity, target imaging, with parallel low acoustic emission. Indocyanine green has the following properties and advantages, which make it an important tool in the applications of medical sciences and studies. Following intravenous administration, it binds to plasma lipoproteins with minimal escape into the interstitial space. Extremely important for its clinical use is the complete excretion through the bile, as well as the non-production of metabolic products. It has low toxicity in the absence of ionization, which in combination with the short half-life of the substance, provides safety for the patient in its use and application in medical and biomedical sciences. It has low costs that in combination with its ease of use facilitates its application. No expensive equipment or large learning curve required. Also the possibility of recurrence with re-administration intraoperatively can offer a number of applications in laparoscopic surgery. It has a low rate of side effects and interactions with other drugs and preparations, a major allergic reaction has been reported in the literature. The first clinical applications of indocyanine green were to assess cardiac function, liver function in cirrhotic patients before hepatectomy, and to examine the retinal vessels. Its use in laparoscopic cholecystectomy, as already mentioned, is based on its ability to fluoresce when exposed to infrared light and in combination with the fact that when administered intravenously it is concentrated and excreted from the bile offers the possibility of intraoperative, fluorescent cholangiography that aims to identify the elements of the Callot triangle. This study aims to demonstrate that endocyanin green cholangiography is equivalent to or better than conventional cholangiography for the diagnosis of cholelithiasis and biliary injuries. It is therefore an important clinical application that will probably facilitate surgeons both in the prevention of biliary injuries and in the intraoperative diagnosis of cholelithiasis. Patients who will undergo laparoscopic cholecystectomy will be randomly divided into 3 (three) groups. The processing of the results will be done in the appropriate way and method. A total of 240 patients will be randomized into three groups of 80. In the first group (A) classical cholangiography will be performed. In group (B) will be performed intravenous fluorescent cholangiography with indocyanine green 6 (six) hours before the start of surgery. In the third group (C) will be performed intraoperative cholangiography with direct administration of indocyanine green to the gallbladder.

Interventions

PROCEDUREIndocyanine Green (ICG) administration

Patients will undergo laparoscopic cholecystectomy after they are randomly divided into 3 (three) groups. A total of 240 patients will be randomized into three groups of 80. In the first group (A) standard cholangiography will be performed. In group (B) intravenous fluorescent cholangiography with indocyanine green will be performed during surgery. ICG at a dose of 0.3 mg / mL / Kg 6 (six) hours prior to surgery will be administered. In the third group (C), intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the gallbladder.

Sponsors

George Papanicolaou Hospital
CollaboratorOTHER
Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. age older than 18 years old 2. laparoscopic cholecystectomy 3. elective surgery

Exclusion criteria

1. younger than 18 years old 2. no consent to participate to the study 3. history of allergic reaction to iodine products 4. urgent or emergent cholecystectomy

Design outcomes

Primary

MeasureTime frameDescription
successful imaging of biliary systemintra-operativelyThe anatomy of the extrahepatic bile ducts will be orally determined by the surgeon and the cases in which the oral description will coincide with the findings of cholangiography or not and where there were differences will be recorded.
operation durationintra-operativelyminutes
intra-operative complications (bleeding, bile duct leakage, bile duct injury)intra-operativelypresence or absence
applicability of the intra-operatively cholangiographyintra-operativelyyes or no
presence of bile duct stones (choledocholithiasis)intra-operativelyyes or no

Secondary

MeasureTime frameDescription
SGOT24 hours prior to surgery and 24 hours after the surgeryg/dL
SGPT24 hours prior to surgery and 24 hours after the surgeryg/dL
ALP24 hours prior to surgery and 24 hours after the surgeryg/dL
γ-GT24 hours prior to surgery and 24 hours after the surgeryg/dL
total bilirubin24 hours prior to surgery and 24 hours after the surgerymg/dL
indirect bilirubin24 hours prior to surgery and 24 hours after the surgerymg/dL
direct bilirubin24 hours prior to surgery and 24 hours after the surgerymg/dL
PT24 hours prior to surgery and 24 hours after the surgeryseconds
INR24 hours prior to surgery and 24 hours after the surgerynumber
genderpre-operativelymale or female
urea24 hours prior to surgery and 24 hours after the surgerymg/dL
creatinine24 hours prior to surgery and 24 hours after the surgerymg/dL
CRP24 hours prior to surgery and 24 hours after the surgerymg/L
WBC24 hours prior to surgery and 24 hours after the surgerymm3/L
ESR24 hours prior to surgery and 24 hours after the surgerymm
procalcitonin24 hours prior to surgery and 24 hours after the surgerymg/dL
TNF-a24 hours prior to surgery and 24 hours after the surgerypg/ml
IL-624 hours prior to surgery and 24 hours after the surgerypg/ml
aPTT24 hours prior to surgery and 24 hours after the surgeryseconds
ASA scorepre-operativelynumber
agepre-operativelyyears
body mass indexpre-operativelykg/m2
indication for laparoscopic cholecystectomypre-operativelyyes or no

Countries

Greece

Contacts

Primary ContactSavvas Simeonidis, MD, PhD(c)
simeonidissavvas@yahoo.com698 0309611
Backup ContactPanagiotis Christidis, MD, MSc
panagiotischristidis13@gmail.com6940730227

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026